

Corporate Contact:

Dr. Kai Holtmann
Investor Relations Manager
Phone: +49 421 224 95 63
E-mail: ir@mevis.de

CORPORATE NEWS

Change in the Supervisory Board of MeVis Medical Solutions AG

Peter Kuhlmann-Lehmkuhle replaces Dr. Peter Zencke

Bremen, June 20, 2011 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software company in medical imaging, today announced a change in their Supervisory Board.

Mr. Peter Kuhlmann-Lehmkuhle, Managing Partner of C. Melchers GmbH & Co. KG, was elected to the Supervisory Board in the company's Annual General Meeting on June 15, 2011. Simultaneously, the previous Supervisory Board Members Prof. Dr. Heinz-Otto Peitgen and Dr. Jens Kruse were elected to the company's control panel. Mr. Kuhlmann-Lehmkuhle is replacing the former Supervisory Board member Dr. Peter Zencke, who has not been available for a new term.

*Peter Kuhlmann-
Lehmkuhle elected by
Annual General Meeting*

"With Peter Kuhlmann-Lehmkuhle, we have gained an experienced and successful Bremen entrepreneur for our Supervisory Board. Being a pre-IPO shareholder he certainly will shape our future business development. Therefore, we look forward to working with him", says Dr. Carl. J. G. Evertsz, chairman of the MeVis Medical Solutions AG Executive Board. Furthermore, the Executive and Supervisory Board both expressed their gratitude to Dr. Peter Zencke, who will be available to the company as an external consultant.

*Close attendance as
shareholder through pre-
IPO investment*

In the Supervisory Board Meeting held on June 15, 2011, Prof. Dr. Peitgen was elected as Chairman of the Supervisory Board and Dr. Jens Kruse as his Deputy.

For further information please visit <http://www.mevis.de>.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.